Hypercoagulability and High Lipoprotein(a) Levels in Patients with Central Retinal Vein Occlusion

Summary

A series of coagulation parameters and lipoprotein(a) (Lp(a)) were explored in plasma from 40 patients with central retinal vein occlusion (CRVO, non-ischemic type n = 12; ischemic type n = 28) free of local and systemic predisposing factors, 1 to 12 months after the acute event. Forty age- and sex-matched patients with cataract served as controls. Prothrombin fragment 1.2 (FI.2), D-dimer, FVII:C - but not FVII: Ag - were higher and fibrinogen was lower in CRVO patients than in controls. Patients with non-ischemic CRVO had higher FI .2 and FVII:C and lower heparin cofactor II than patients with ischemic CRVO. Lp(a) levels greater than 300 mg/1 were observed in 12 patients with CRVO and in 4 controls (30% vs 10%, p <0.025). Patients with high Lp(a) - consistently associated with the S2 phenotype - had higher FVII:C, FVII:C/Ag ratio, and fibrinogen than the remaining CRVO patients. Plasma FI.2 and D-dimer correlated fairly in controls (r = 0.41) and patients with normal Lp(a) levels (r = 0.55), but they did not in the group of patients with high Lp(a) (r = 0.19), where the latter parameter was negatively related to D-dimer (r = −0.55). There was no dependence of the abnormalities observed on the time elapsed from vein occlusion. The findings of activated FVII and high FI.2, D-dimer, and Lp(a) are not uncommon in patients with CRVO. Increased thrombin formation with fibrin deposition and impaired fibrinolysis may play a role in the pathophysiology of CRVO and require specific treatment

• References

• 1 Appiah AP, Trempe CL. Risk factors associated with branch vs central retinal vein occlusion. Ann Ophthalmol 1989; 21: 153-157
• 2 Gutman FA. Evaluation of patients with central retinal vein occlusion. Ophthalmology 1983; 90: 481-483
• 3 Priluck IA. Impending central retinal vein occlusion associated with increased platelet aggregability. Ann Ophthalmol 1979; 11: 79-84
• 4 Dodson PM, Westwick J, Marks J, Kakkar VV, Galton DJ. B-thromboglo-bulin and platelet factor 4 levels in retinal vein occlusion. Br J Ophthalmol 1983; 67: 143-146
• 5 Pandolfi M, Ericsson S, Astedt B. Coagulation and fibrinolytic studies in 23 patients with occlusion of the retinal vessels. Acta Ophthalmol 1972; 50: 62-72
• 6 Peduzzi M, De Rosa V, Fonda S, Coccheri S. Haemostatic studies in retinal vein occlusion. Fibrinolytic response to venostasis as a prognostic factor for spontaneous recanalization. Thromb Res 1981; 24: 105-118
• 7 Pelosse B, Mussin P, Bousas E. Hemostasis and central retinal vein occlusion. Ophtalmologie 1988; 2: 335-356
• 8 Fitzpatrick EP, Chesen N, Rahn EK. The lupus anticoagulant and retinal vasoocclusive disease. Ann Ophthalmol 1990; 22: 148-152
• 9 Mari D, Santori D, Bertoni G, Mannucci PM. Coagulation and platelet activation after retinal vein occlusion. Haemostasis 1982; 11: 189-192
• 10 Guareschi G, Vigano’ D’Angelo S, Foresti V, Bandello F, D’Angelo A. Normal activities of protein C, protein S and antithrombin III in young patients with retinal vein occlusion. Haematologica 1990; 75: 483-484
• 11 Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339: 301-303
• 12 Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology 1983; 90: 458-474
• 13 Vigano’ D’Angelo S, Comp PC, Esmon CT, D’Angelo A. Relationship between protein C antigen and activity during oral anticoagulation and in selected disease states. J Clin Invest 1986; 77: 416-425
• 14 D’Angelo A, Vigano’ D’Angelo S, Esmon CT, Comp PC. Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, liver disease and in disseminated intravascular coagulation. J Clin Invest 1988; 81: 1445-1454
• 15 Uterman G. The mysteries of lipoprotein (a). Science 1989; 246: 904-910
• 16 Utermann G, Menxel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotype. Inheritance and relation to Lp(a)-lipoprotein concentration in plasma. J Clin Invest 1987; 80: 458-465
• 17 Neave HR, Worthington PL. Distribution-free tests. Routledge, London 1992
• 18 Zenker G, Koltringer P, Bone G, Niederkom K, Pfeiffer K, Jurgens G. Li-poprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986; 17: 942-945
• 19 Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boer-winkle E, Utermann G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. New Engl J Med 1990; 322: 1494-1499
• 20 Kruger K, Anger V. Ischemic occlusion of the central retinal vein and protein C deficiency. J Fr Ophtalmol 1990; 13: 369-371
• 21 Kruger K, Witt I. Inhibitors of blood coagulation in vascular occlusion of the retina and optic nerve. Fortschr Ophthalmol 1990; 87: 178-181
• 22 Tran TH, Marbet GA, Duckert F. Association of hereditary heparin cofactor II deficiency with thrombosis. Lancet 1985; 2: 413-414
• 23 Meade TW, Mellows S, Brozovic M, Miller SG, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thomson SG. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537
• 24 Whilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tribblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
• 25 Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-350
• 26 Wilde JT, Kitchen S, Kinsey S, Greaves M, Preston FE. Plasma D-dimer levels and their relationship to serum fibrinogen/fibrin degradation products in hypercoagulable states. Br J Haematol 1989; 71: 65-70
• 27 Hassar KA, Gavish D, Breslow JC, Nachman RL. Lipoprotein (a) modulation of endothelial surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339: 303-305
• 28 Edelberg JM, Pizzo SV. Lipoprotein (a) promotes plasmin inhibition by a₂-antiplasmin. Biochem J 1992; 286: 79-84
• 29 Halvorsen S, Skjonsberg OH, Berg K, Ruyter R, Godal HC. Does Lp(a) lipoprotein inhibit the fibrinolytic system?. Thromb Res 1992; 68: 223-232
• 30 Aznar J, Estellés A, Bretó M, España F, Alos T. Euglobulin clot lysis induced by tissue-type plasminogen activator is reduced in subjects with increased levels of lipoprotein(a). Thromb Res 1992; 66: 569-582
• 31 Terres W, Krewitt M, Hamm CW. Effects of lipoprotein(a) on in vitro lysis of whole blood thrombi from healthy volunteers. Thromb Res 1993; 69: 479-487
• 32 Simon DI, Fless GM, Scanu AM, Loscalzo J. Tissue-type plasminogen activator binds to and is inhibited by surface bound lipoprotein(a) and low density lipoprotein. Biochemistry 1991; 30: 6671-6677
• 33 Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrin and fibrinogen. Proc Natl Acad Sci USA 1989; 86: 3847-3851
• 34 Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989; 78: 145-150
• 35 Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs H. Apolipo-protein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90: 52-60
• 36 Esnouf MP, Mitropoulos KA, Burgess AI. The relation of hyperlipidaemia to the hypercoagulable state. In: Thrombosis an update Neri Semeri G, Gensini GF, Abbate R, Prisco D. (eds). Scientific Press; Florence, Italy: 1992: 715-725
• 37 Miler WF, Blumenkranz M. Long-term vein occlusion. Risk factors, status of the fellow eye. Invest Ophthalmol Vis Sci 1982; 23 (Suppl. 04) 69
• 38 Kohner EM, Laatikainen L, Oughton J. The management of central retinal vein occlusion. Ophthalmology 1983; 90: 484-487
• 39 Gurakar A, Hoeg KM, Kostner G, Papadopoulos NM, Brewer Jr HB. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 1985; 57: 293-301
• 40 Seed M, O’Connor B, Perombelon N, O’Donnell M, Reaveley D, Knight BL. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis 1993; 101: 61-68